Arthneeti
Latest: Marksans Pharma Ltd Q1 FY27 results →All Q4 FY26 results →
MP

Marksans Pharma Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Marksans Pharma Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Price₹321
Market cap₹12.3K Cr
P/E29.5
Updated23 Aug 2026
Read5 min read

Marksans Pharma Ltd Q4 FY26 key numbers

Revenue
Australia is expected to reach $100 million in revenue within 3 years, with ongoing new product launches.

As stated in Marksans Pharma Ltd's Q4 FY26 earnings call transcript · published 13 Jun 2026. Reported figures, not investment advice.

The short version

Marksans Pharma targets to double revenue in the next 3 to 5 years, aiming for INR4,000 crores by FY28. - Growth drivers include strong expansion in the U.S. Marksans Pharma aims to double its revenue in the next 3 to 5 years, targeting INR4,000 crores by FY28. - Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) margin guidance remains stable at around 20-22%, despite raw material inflation pressures. - Profit after tax and Earnings Per Share (EPS) showed strong growth in FY26 with a 64.3% increase in PAT and EPS reaching INR9.2. - The company expects continued growth driven by diversification into new geographies like Europe (Germany, Canada), strong U.S.

From Marksans Pharma Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • Marksans Pharma targets to double revenue in the next 3 to 5 years, aiming for INR4,000 crores by FY28.
  • Growth drivers include strong expansion in the U.S. market, Europe (especially U.K. and Germany), and Australia/New Zealand.
  • Australia is expected to reach $100 million in revenue within 3 years, with ongoing new product launches.
  • Europe and Canada markets are being developed organically, with product filings underway and revenue expected to start trickling in by late FY27.
  • Capacity utilization currently about 50-55%, with spare capacity to support growth before expansion.
  • The company plans to file over 200 products in the U.K. over the next 4 years, expanding the product pipeline continuously.

2 more points from Marksans Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Marksans Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Capex during FY26 was INR131 crores, primarily for the new facility and ongoing maintenance.
  • Major capex cycle now complete, with free cash flow generation improving steadily.
  • Management actively exploring acquisition targets for strategic growth; ongoing due diligence on two potential targets.
  • 2027 expected to see some M&A activity funded by INR990 crores cash balance.
  • Focus on value-accretive acquisitions across different geographies, conservatively valued to ensure return on investment.

2 more points from Marksans Pharma Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Marksans Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Some related points to their business outlook and growth plans include: - Strong growth in multiple geographies like U.S., Europe (including U.K.), Australia, and Canada with an expanding product pipeline. - A healthy and growing product pipeline, with about 50+ new products expected for filing in the U.S. in FY27 and larger pipelines in other geographies. - Canada products are under filing with expected approvals in late FY26. - Australia/New Zealand business targeting $100 million revenue milestone within 3 years. - Focus on acquiring and integrating new assets in key geographies to diversify platforms.

2 more points from Marksans Pharma Ltd's call on order book

Create a free account to keep reading this call

What the Q4 FY26 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned

Marksans Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹856 Cr, net profit ₹149 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Marksans Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharmaceuticals Ltd (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals Ltd (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn Ltd (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma Ltd (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Marksans Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Marksans Pharma Ltd Q4 FY26 results?

Marksans Pharma targets to double revenue in the next 3 to 5 years, aiming for INR4,000 crores by FY28. - Growth drivers include strong expansion in the U.S. Marksans Pharma aims to double its revenue in the next 3 to 5 years, targeting INR4,000 crores by FY28. - Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) margin guidance remains stable at around 20-22%, despite raw material inflation pressures. - Profit after tax and Earnings Per Share (EPS) showed strong growth in FY26 with a 64.3% increase in PAT and EPS reaching INR9.2. - The company expects continued growth driven by diversification into new geographies like Europe (Germany, Canada), strong U.S.

What is Marksans Pharma Ltd share price analysis?

Marksans Pharma Ltd currently shows a below-average growth signal. The stock trades at a P/E of 29.4 with a market cap of ₹12,265 Cr. Investors should review the full earnings analysis for detailed insights.

Is Marksans Pharma Ltd planning capital expenditure?

Capex during FY26 was INR131 crores, primarily for the new facility and ongoing maintenance.

Keep Marksans Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.